Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Complement factor B inhibitors and uses there of

a technology of complement factor and inhibitor, which is applied in the field of inhibitors of complement factor b, can solve the problems of deterioration of sight, retinal displacement, hemorrhage and scarring, and increase the risk of age-related macular degeneration

Inactive Publication Date: 2016-10-25
NOVARTIS AG
View PDF48 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent provides compounds that can inhibit the activation of the complement system, specifically the alternative pathway. These compounds target the protein Factor B and prevent it from causing damage. The invention covers various forms of these compounds and pharmaceutical compositions containing them. The technical effect of this invention is that it provides a potential treatment for complement-mediated diseases such as ophthalmic, autoimmune, respiratory, and cardiovascular diseases.

Problems solved by technology

Neovascular AMD is characterized by the abnormal growth of blood vessels under the macula and vascular leakage, resulting in displacement of the retina, hemorrhage and scarring.
This results in a deterioration of sight over a period of weeks to years.
Complement factor H variant increases the risk of age-related macular degeneration.
Currently there is no proven medical therapy for dry AMD and many patients with neovascular AMD become legally blind despite current therapy with anti-VEGF agents such as Lucentis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Complement factor B inhibitors and uses there of
  • Complement factor B inhibitors and uses there of
  • Complement factor B inhibitors and uses there of

Examples

Experimental program
Comparison scheme
Effect test

biological example 1

Human Complement Factor B ELISA Assay

[0368]CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purified using standard methods) and human complement factor D (expressed in E. Coli, refolded and purified using standard methods). CVF-Bb complex at 3 nM concentration was incubated with test compound at various concentrations for 1 hour at room temperature in PBS pH 7.4 containing 10 mM MgCl2 and 0.05% (w / v) CHAPS. Human complement C3 substrate purified from plasma was added to a final concentration of 1 μM. After 1 hour incubation at room temperature, the enzyme reaction was stopped by addition of a cocktail of concentrated pan-protease inhibitors. The product of the reaction, C3a, was quantified by means of an enzyme-linked-immunosorbent assay. IC50 values were calculated from percentage of inhibition of CVF-Bb activity as a function of test compound concentration.

biological example 2

Human Complement Factor B TR-FRET Assay

biological example 2.1

(+) or (−)-tert-Butyl 3-(3-hydroxyphenyl)piperazine-1-carboxylate

[0369]

[0370]Resolution of the enantiomers of (±)-tert-butyl 3-(3-hydroxyphenyl)piperazine-1-carboxylate (CAS#889956-76-7) was achieved by chiral HPLC using a CHIRALPAK AD column with heptane / EtOAc / MeOH 90 / 5 / 5+0.1 diethylamine to give (+) or (−)-tert-butyl 3-(3-hydroxyphenyl)piperazine-1-carboxylate (tr=9.7 min) and (−) or (−)-tert-butyl 3-(3-hydroxyphenyl)piperazine-1-carboxylate (tr=15.7 min).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
temperaturesaaaaaaaaaa
enantiomeric excessaaaaaaaaaa
Login to View More

Abstract

The present invention provides a compound of formula (I): wherein X is N or CH, Y is NH, O or S, methods for manufacturing these compounds, and their uses as Factor B inhibitors for the treatment of conditions and diseases associated with complement alternative pathway activation such as age-related macular degeneration, diabetic retinopathy and related ophthalmic diseases. The present invention further provides pharmaceutical compositions and combinations of pharmacologically active agents.

Description

[0001]The application is a U.S. National Phase filing of International Application No. PCT / US2014 / 026875filed 13 Mar. 2014, which claims priority to U.S. Application No. 61 / 782,750 filed 14 Mar. 2013, the contents of which are incorporated herein by reference in their entirety.RELATED APPLICATIONS[0002]This application claims priority to U.S. Provisional Application No. 61 / 782,750 filed on Mar. 18, 2013, the contents of which are incorporated herein by reference in their entirety.FIELD OF THE INVENTION[0003]The invention relates to the inhibition of the complement alternative pathway and particularly to inhibition of Factor B, in patients suffering from conditions and diseases associated with complement alternative pathway activation such as age-related macular degeneration, diabetic retinopathy and related ophthalmic diseases.BACKGROUND OF THE INVENTION[0004]The complement system is a crucial component of the innate immunity system and comprises a group of proteins that are normall...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): C07D401/14A61K31/437C07D471/04A61K31/4353
CPCC07D471/04A61P1/04A61P3/04A61P3/06A61P9/10A61P11/00A61P11/06A61P13/12A61P21/04A61P25/00A61P25/16A61P27/02A61P29/00A61P31/04A61P33/00A61P37/02A61P37/06A61P37/08A61P43/00
Inventor ADAMS, CHRISTOPHER MICHAELBABU, CHARLESCAPPARELLI, MICHAEL PAULDING, JIANEHARA, TAKERUJENDZA, KEITHJI, NANKARKI, RAJESHRI GANESHKAWANAMI, TOSHIOXUE, LIANGMAINOLFI, NELLOPOWERS, JAMES J.SERRANO-WU, MICHAEL H.ZHANG, CHUN
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com